Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

Rhea-AI Summary

Anixa Biosciences (NASDAQ: ANIX) announced a presentation of its breast cancer vaccine trial at the ASCO Annual Meeting on June 3-7, 2022. The presentation, led by Dr. George Thomas Budd of Cleveland Clinic, focuses on a Phase 1 trial of an alpha-Lactalbumin vaccine for patients with operable triple-negative breast cancer (TNBC). With TNBC being a significant challenge in oncology, accounting for a high percentage of breast cancer deaths, Anixa’s approach targets proteins unique to this cancer type. The vaccine aims to activate the immune system for early tumor prevention.

Positive

• Presentation of Phase 1 trial of breast cancer vaccine at ASCO meeting, enhancing visibility.
• Targeting triple-negative breast cancer, a severe variant with high mortality.
• Collaboration with Cleveland Clinic, leveraging expertise for vaccine development.

Negative

• Ongoing Phase 1 trial indicates early-stage development, with uncertain future outcomes.
• Clinical trials inherently carry risks, including potential failure to demonstrate efficacy.

SAN JOSE, Calif., April 28, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced a presentation outlining the design of its breast cancer vaccine trial at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3-7, 2022. The presentation, titled "Phase 1 Trial of an alpha-Lactalbumin vaccine in patients with moderate- to high-risk operable triple-negative breast cancer (TNBC)" will be presented by the study's principal investigator, Dr. George Thomas Budd of Cleveland Clinic, Anixa's collaboration partner.

Additional presentation details can be found below:

Abstract #: TPS1125

Date/Time: June 6, 2022, 9:00 AM EDT

About Triple-Negative Breast Cancer

One in eight women in the U.S. will be diagnosed with an invasive breast cancer at some point in their lives. Approximately 10-15% of those diagnoses are TNBC, however TNBC accounts for a disproportionately higher percentage of breast cancer deaths and has a higher rate of recurrence. This form of breast cancer is twice as likely to occur in African-American women, and approximately 70% to 80% of the breast tumors that occur in women with mutations in the BRCA1 genes are triple-negative breast cancer.

About Anixa Bioscience's Breast Cancer Vaccine

Anixa's investigational vaccine, currently in Phase 1 trials, takes advantage of endogenously produced proteins that have a function at certain times in life, but then become "retired" and disappear from the body. One such protein is a breast-specific lactation protein, α-lactalbumin, which is no longer found post-lactation in normal, aging tissues, but is present in the majority of triple-negative breast cancers. Activating the immune system against this "retired" protein provides preemptive immune protection against emerging breast tumors that express α-lactalbumin. The vaccine also contains an adjuvant that activates an innate immune response, which allows the immune system to mount a response against emerging tumors to prevent them from growing.

About Anixa Biosciences, Inc.

Anixa is a clinical-stage biotechnology company with a number of programs addressing cancer and infectious disease. Anixa's portfolio of therapeutics includes a cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and, with partner MolGenie GmbH, a COVID-19 program focused on compounds targeting the M^pro enzyme of SARS-CoV-2, which is largely conserved across all recently identified variants like Delta and Omicron. The company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – as well as a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on clinical development allows the company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn and Facebook.

Forward-Looking Statements

Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Contacts

Company Contact:
Mike Catelani
President
mcatelani@anixa.com
408-708-9808

Media:
Slavena Salve Nissan, M.D.
LifeSci Communications
snissan@lifescicomms.com
718-483-4440

Investors:
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
646-751-4363

View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-announces-presentation-on-breast-cancer-vaccine-trial-at-the-american-society-of-clinical-oncology-asco-annual-meeting-301535271.html

SOURCE Anixa Biosciences, Inc.

FAQ

What is Anixa Biosciences' upcoming presentation about?

Anixa Biosciences will present its breast cancer vaccine trial at the ASCO Annual Meeting on June 6, 2022.

What is the focus of the Phase 1 trial presented by Anixa?

The trial focuses on an alpha-Lactalbumin vaccine for patients with operable triple-negative breast cancer.

When will Anixa present at the ASCO Annual Meeting?

Anixa's presentation is scheduled for June 6, 2022, at 9:00 AM EDT.

What is triple-negative breast cancer?

Triple-negative breast cancer (TNBC) is a subtype of breast cancer that is more aggressive and has fewer treatment options.

How does Anixa's breast cancer vaccine work?

The vaccine aims to activate the immune system against 'retired' proteins that are present in most triple-negative breast cancers.